Back to Journals » OncoTargets and Therapy » Volume 11

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Total article views   Abstract views HTML views PDF downloads Totals
5,142 Dovepress* 3,971 692+ 568 4,663
PubMed Central* 0 479 110 479
Totals 3,971 1,171 678 5,142
*Since 11 April 2018
+Since July 2016

View citations on PubMed Central and Google Scholar